KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Account Payables (2018 - 2025)

Moderna (MRNA) has disclosed Change in Account Payables for 8 consecutive years, with $22.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 35.29% to $22.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$92.0 million through Dec 2025, down 33.33% year-over-year, with the annual reading at -$92.0 million for FY2025, 33.33% down from the prior year.
  • Change in Account Payables for Q4 2025 was $22.0 million at Moderna, down from $89.0 million in the prior quarter.
  • The five-year high for Change in Account Payables was $179.0 million in Q3 2023, with the low at -$303.0 million in Q1 2024.
  • Average Change in Account Payables over 5 years is $14.8 million, with a median of $21.5 million recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 9000.0% in 2021, while the deepest fall reached 1000.0% in 2021.
  • Over 5 years, Change in Account Payables stood at $178.0 million in 2021, then dropped by 15.17% to $151.0 million in 2022, then crashed by 86.09% to $21.0 million in 2023, then surged by 61.9% to $34.0 million in 2024, then tumbled by 35.29% to $22.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $22.0 million, $89.0 million, and -$47.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.